Adverum Biotechnologies, Inc.
ADVMNASDAQHealthcare
$4.36
+$0.00(+0.00%)
Market Cap$96257756
P/E Ratio—
52W High$6.07
52W Low$1.78
Adverum Biotechnologies, Inc. (ADVM) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ADVM · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2025Report Date: Nov 12, 2025EPS Actual
-$2.03
Est. -$1.80 · -12.8%
Revenue
—
Est. $0.00B
Fiscal Period
Q4 FY2025
FY ends December
Report Date
Nov 12, 2025
After Market Close
▼ Miss EPS
ADVM reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▼ Q4 FY2025 | Nov 12, 2025 | -$1.80 | -$2.03 | -12.8% | — | $0.00B | — |
| ▼ Q3 FY2025 | Aug 12, 2025 | -$2.24 | -$2.34 | -4.5% | — | — | — |
| ▼ Q2 FY2025 | Apr 15, 2025 | -$1.81 | -$1.96 | -8.3% | — | — | — |
| ▼ Q1 FY2025 | Mar 24, 2025 | -$1.31 | -$1.57 | -20.1% | $-0.00B | — | — |
| ▼ Q4 FY2024 | Nov 4, 2024 | -$1.20 | -$1.30 | -8.3% | $0.00B | $0.00B | +700.0% |
| ▲ Q3 FY2024 | Aug 12, 2024 | -$1.27 | -$0.89 | +29.9% | — | $0.00B | — |
| ▼ Q2 FY2024 | May 9, 2024 | -$1.28 | -$1.50 | -17.2% | — | $0.00B | — |
| ▲ Q1 FY2024 | Mar 18, 2024 | -$2.80 | -$2.30 | +17.9% | $-0.00B | — | — |
Q4 FY2025
Nov 12, 2025Miss
EPS Actual
-$2.03
EPS Est.
-$1.80
EPS Surpr.
-12.8%
Revenue
—
Q3 FY2025
Aug 12, 2025Miss
EPS Actual
-$2.34
EPS Est.
-$2.24
EPS Surpr.
-4.5%
Revenue
—
Q2 FY2025
Apr 15, 2025Miss
EPS Actual
-$1.96
EPS Est.
-$1.81
EPS Surpr.
-8.3%
Revenue
—
Q1 FY2025
Mar 24, 2025Miss
EPS Actual
-$1.57
EPS Est.
-$1.31
EPS Surpr.
-20.1%
Revenue
$-0.00B
Q4 FY2024
Nov 4, 2024Miss
EPS Actual
-$1.30
EPS Est.
-$1.20
EPS Surpr.
-8.3%
Revenue
$0.00B
Q3 FY2024
Aug 12, 2024Beat
EPS Actual
-$0.89
EPS Est.
-$1.27
EPS Surpr.
+29.9%
Revenue
—
Q2 FY2024
May 9, 2024Miss
EPS Actual
-$1.50
EPS Est.
-$1.28
EPS Surpr.
-17.2%
Revenue
—
Q1 FY2024
Mar 18, 2024Beat
EPS Actual
-$2.30
EPS Est.
-$2.80
EPS Surpr.
+17.9%
Revenue
$-0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-1.30 | $-1.30 | $-1.30 | 1 |
| Q3 FY2026 | $-1.26 | $-1.26 | $-1.26 | 1 |
| Q2 FY2026 | $-1.21 | $-1.21 | $-1.21 | 1 |
| Q1 FY2026 | $-2.09 | $-1.24 | $-0.37 | 2 |
| Q4 FY2025 | $-2.97 | $-1.72 | $-0.47 | 3 |
| Q3 FY2025 | $-2.39 | $-1.75 | $-0.82 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q4 FY2025 | Nov 12, 2025 | -12.8% | $4.33 | $4.30 | -0.69% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -4.5% | $2.24 | $2.47 | +10.27% |
| ▼ Q2 FY2025 | Apr 15, 2025 | -8.3% | $3.43 | $3.23 | -5.83% |
| ▼ Q1 FY2025 | Mar 24, 2025 | -20.1% | $5.10 | $5.40 | +5.88% |
| ▼ Q4 FY2024 | Nov 4, 2024 | -8.3% | $7.41 | $7.54 | +1.75% |
| ▲ Q3 FY2024 | Aug 12, 2024 | +29.9% | $6.56 | $6.49 | -1.07% |
| ▼ Q2 FY2024 | May 9, 2024 | -17.2% | $9.81 | $9.61 | -2.04% |
| ▲ Q1 FY2024 | Mar 18, 2024 | +17.9% | $17.00 | $17.70 | +4.12% |
Q4 FY2025-0.69%
Report Date
Nov 12, 2025
EPS Beat/Miss
-12.8%
Price Before
$4.33
Price After
$4.30
Q3 FY2025+10.27%
Report Date
Aug 12, 2025
EPS Beat/Miss
-4.5%
Price Before
$2.24
Price After
$2.47
Q2 FY2025-5.83%
Report Date
Apr 15, 2025
EPS Beat/Miss
-8.3%
Price Before
$3.43
Price After
$3.23
Q1 FY2025+5.88%
Report Date
Mar 24, 2025
EPS Beat/Miss
-20.1%
Price Before
$5.10
Price After
$5.40
Q4 FY2024+1.75%
Report Date
Nov 4, 2024
EPS Beat/Miss
-8.3%
Price Before
$7.41
Price After
$7.54
Q3 FY2024-1.07%
Report Date
Aug 12, 2024
EPS Beat/Miss
+29.9%
Price Before
$6.56
Price After
$6.49
Q2 FY2024-2.04%
Report Date
May 9, 2024
EPS Beat/Miss
-17.2%
Price Before
$9.81
Price After
$9.61
Q1 FY2024+4.12%
Report Date
Mar 18, 2024
EPS Beat/Miss
+17.9%
Price Before
$17.00
Price After
$17.70
Avg Beat Reaction+1.52%
Avg Miss Reaction+1.56%
Beat Rate2 / 8 quarters
Largest Move+10.27% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ADVM ends December
Adverum Biotechnologies, Inc. (ADVM) most recently reported earnings on November 12, 2025 for Q4 FY2025, posting EPS of $-2.03 — missing the analyst consensus of $-1.80 by -12.8%. The next ADVM earnings date is expected around September 1, 2026.
Each quarter, investors track ADVM earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ADVM revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ADVM's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ADVM earnings · 5 questionsAdverum Biotechnologies, Inc.'s next earnings report is expected around September 1, 2026. ADVM typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ADVM historically reports after market close (AMC).
ADVM earnings datewhen is ADVM earningsADVM next earnings datewhen does ADVM report earningsADVM earnings calendar
▸ Source: FMP · Adverum Biotechnologies, Inc. SEC filings · US GAAP · Adverum Biotechnologies, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026